Transgene operates in the Biological products exc. diagnostic sector. Transgene SA is a France-based biopharmaceutical company engaged in the discovery and development of gene-based therapeutic vaccines and immunotherapy products for the treatment of cancer and infectious diseases. Its products include treatments for non small cell lung cancer and metastatic colorectal cancer, as well as chronic hepatitis C, cervical intraepithelial neoplasia and others.The Company implements its business strategy by developing vaccines and products in specific indications and partnering with pharmaceutical companies for later stage development; independently developing and commercializing vaccines and products for certain special markets. The Company operates through two French sites, Transgene Tasly and Platine SAS and one fully owned subsidiary in the United States, Transgene, Inc. As of December 31, 2012, the Company created a subsidiary Transgene Biopharmaceuticals Technology in China. In our complete report available for purchase the company is compared to: Vivalis, Nicox SA and Exonhit Therapeutics SA.